Comparative Pharmacology
Head-to-head clinical analysis: SULFOSE versus TRIPLE SULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFOSE versus TRIPLE SULFOID.
SULFOSE vs TRIPLE SULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic